# Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

> **NCT05429684** · PHASE3 · UNKNOWN · sponsor: **First Affiliated Hospital Xi'an Jiaotong University** · enrollment: 120 (estimated)

## Conditions studied

- HER2+ Breast Cancer

## Interventions

- **DRUG:** Trastuzumab
- **DRUG:** Pertuzumab
- **DRUG:** Nab paclitaxel
- **DRUG:** Pyrotinib
- **DRUG:** Capecitabine
- **DRUG:** T-DM1
- **DRUG:** Everolimus
- **DRUG:** CDK4/6 inhibitor
- **DRUG:** AI
- **DRUG:** Anti-PD-1 monoclonal antibody

## Key facts

- **NCT ID:** NCT05429684
- **Lead sponsor:** First Affiliated Hospital Xi'an Jiaotong University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-01
- **Primary completion:** 2024-02-28
- **Final completion:** 2024-02-28
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2022-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05429684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05429684, "Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05429684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*